This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future.

How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights.

Transform your DTC marketing with AI-powered precision targeting. Drive better patient outcomes and commercial success through privacy-safe engagement. Download now to learn more.

AI is revolutionizing the drug development process, streamlining and accelerating every stage, from research to approval and marketing. This whitepaper explores the benefits and risks of AI in the pharmaceutical industry and examines its future. 

Antibody-drug conjugates (ADCs) and radioisotope therapies (RITs) offer targeted therapies that effectively attack tumor cells while minimizing harm to surrounding healthy tissue. However, getting the design of ADC and RIT trials right is critical. This resource explores the pivotal role advanced medical imaging plays in improving clinical trial design and patient access to cutting-edge treatment options.

We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned.

See how Guardant Health is increasing access to in-country liquid biopsy testing through partnerships with world-renowned labs and academic centers around the globe. Download Now.

Single cell RNA sequencing uncovers tissue heterogeneity by providing gene expression measurements in individual cells within the tissue. This level of resolution allows for a clearer understanding of specific cellular functions, tissue complexity, and is a powerful tool to discover therapeutic targets and novel biomarkers. Download now to learn more.